WWW.ABSTRACT.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Abstract, dissertation, book
 
<< HOME
CONTACTS



Pages:     | 1 | 2 || 4 | 5 |   ...   | 11 |

«Dissertation Zur Erlangung des Doktorgrades der Naturwissenschaften Der Fakultät für Mathematik, Informatik und Naturwissenschaften der ...»

-- [ Page 3 ] --

This retention could be minimized by using either a diluted drug solution or PVP as crystallization inhibitor [18, 25]. Moreover, PVP may also act as binder during compaction leading to an increase of the liquid load factor [18].

The release rate of a drug from a dosage form is dependent on its disintegration and the dissolution rate of the drug. Therefore, it is very important for liquisolid systems with enhanced drug release to ensure that disintegration is not the rate-limiting step and drug dissolution is not hindered by a slow disintegration of the dosage form. It was found that the release rate increases by addition of superdisintegrants such as sodium starch glycolate or croscarmellose sodium to the liquisolid formulation [6, 16, 20].

Liquisolid Technology 16 Another formulation parameter that may be optimized is the ratio of carrier to coating material (R). An increase in the R-value results in an enhanced release rate if microcrystalline cellulose and colloidal silica are used as carrier and coating materials, respectively. Liquisolid compacts with high R-values contain high amounts of microcrystalline cellulose, low quantities of colloidal silica, and low liquid/powder ratios.

This is associated with enhanced wicking, disintegration and thus, enhanced drug release. In contrast, if high amounts of colloidal silica are used, which means that the R-value is low, the liquisolid compact is overloaded with liquid formulation due to a high liquid load factor. In such cases, even though drug diffusion out of the primary particles may be rapid, oversaturation might occur resulting in local precipitation/ recrystallization of the drug and thus decreased release rates [18, 29]. Moreover, as colloidal silica is a hydrophobic material high amounts of it can cause retardation of drug release. Therefore, Spireas et al. recommend a minimum R-value of 20 [29]. In the case of liquisolid sustained release compacts lower R-values may be used [34, 35] (see below).

Liquisolid Technology 17

1.3.3 Stability of liquisolid systems with enhanced drug release

To obtain information on the stability of liquisolid systems, the effects of storage on the release profile and the crushing strength of liquisolid compacts were investigated.

Stability studies of liquisolid systems containing polythiazide (40 °C/ 42 and 75 % R.H., 12 weeks) [32], hydrocortisone (ambient conditions, 10 months) [1], carbamazepine (25 °C/ 75 % R.H., 6 months) [18], indomethacin (25 °C/ 75 % R.H., 12 months) [28], piroxicam (25 °C/ 75 % R.H., 6 and 9 months, respectively) [4, 31], or naproxen (20 °C/ 76 % R.H., 4 weeks) [30] showed that storage at different conditions neither had an effect on the hardness nor on the release profiles of liquisolid compacts. This indicates that the technology is a promising technique to enhance the release rate without having any physical stability issues.

Liquisolid Technology 18

1.4 Liquisolid formulations for sustained drug release

Numerous methods have been described to produce sustained release formulations, among which the liquisolid technology is a quite new and promising technology resulting in a sustained release pattern with zero order kinetics [8, 12]. So far, only few drugs have been formulated as liquisolid systems with prolonged drug release. In Table 4 the fomulations of these drugs with the respective liquid vehicle, carrier and coating material as well as the additional retarding agent (matrix forming material) are listed.

Table 4: Formulations of liquisolid systems with sustained drug release (abbreviations are listed at the end of the table)

–  –  –

1.4.1 Mechanisms of sustained drug release from liquisolid systems With X-ray crystallography and DSC measurements it could be confirmed, that sustained drug release from these liquisolid compacts is not caused by a change in crystallinity or by complex formation of the drug during the manufacturing process of the sustained release liquisolid formulations [36, 37]. Liquisolid formulations with sustained drug release may contain hydrophobic carriers such as Eudragit® RL or RS instead of hydrophilic carriers, the latter being used for fast release liquisolid formulations [37, 38]. Hydrophobic carriers may lead to poor wetting properties of the compacts resulting in slow disintegration and thus, prolonged drug release.

Furthermore, the liquid vehicle may affect drug release. A comparison of drug release from conventional matrix tablets (direct compression) and liquisolid compacts, both containing Eudragit® RS or RL as matrix forming material, showed that the retardation effect of liquisolid compacts with polysorbate 80 as liquid vehicle is much more pronounced than that of conventional matrix tablets [37, 38]. This confirms the important role of the liquid vehicle in sustaining drug release from liquisolid matrix systems. It was shown that the liquid vehicle polysorbate 80 may act as a plasticizer [40] and thus, decreases the glass transition temperature of the polymer Eudragit® RS.

Accordingly, with liquisolid compacts the coalescence of the polymer particles occurs at lower temperatures than with conventional matrix tablets. This more pronounced coalescence of polymer particles of liquisolid compacts leads to a matrix with lower porosity and higher tortuosity. Consequently, the drug is surrounded by a fine network of the hydrophobic polymer resulting in a sustained release of the drug [41, 42].





Moreover, it has been shown that the addition of hydroxypropyl methylcellulose (HPMC) increases the retardation effect of liquisolid compacts [1, 13]. HPMC is commonly used for the preparation of hydrophilic matrix systems. Depending on its molecular weight the polymer either swells in contact with water and forms a hydrated matrix layer through which the drug has to diffuse or erodes resulting in a zero order drug release kinetic [43]. In the case of HPMC it was also found that a stronger retardation effect was observed with liquisolid compacts as compared to directly compressed tablets (conventional formulation) [38].

Liquisolid Technology 20 1.4.2 Optimization of liquisolid formulations with sustained drug release In contrast to liquisolid compacts with immediate drug release liquisolid sustained release formulations may be optimized by selection of low R-values, suspensions with a high percentage of undissolved drug and by avoidance of disintegrants.

If the R-value is low, which means that the applied amount of silica is high, the liquisolid compacts are overloaded with liquid formulation due to a high liquid load factor. In such cases oversaturation might occur resulting in local precipitation of the drug and thus, decreased release rates [18, 29]. Moreover, the higher the percentages of undissolved drug in the liquid formulation the slower the release rate. This is especially important for poorly soluble drugs, as the dissolution rate of these drugs is low. In addition, as drug release from a tablet is dependent on the disintegration of the tablet and the subsequent dissolution of the drug, the absence of disintegrants, which prevents disintegration, will slow down drug release.

–  –  –

1.5 In vivo evaluation of immediate release liquisolid systems The liquisolid technology is a promising approach for the enhancement of drug release of poorly soluble drugs as described in subchapter 1.3. However, the improved bioavailability to be expected from liquisolid systems has not been investigated in detail.

Khaled et al. studied the absorption characteristics of hydrochlorothiazide liquisolid compacts in comparison with commercial tablets in beagle dogs [10]. Significant differences in the area under the plasma concentration-time curve, the peak plasma concentration, and the absolute bioavailability of the liquisolid and the commercial tablets were observed. However, for the mean residence time, the mean absorption time, and the rate of absorption no significant differences were found. The absolute bioavailability of the drug from liquisolid compacts was 15 % higher than that from the commercial formulation.

Fahmy et al. investigated the in vitro and in vivo performance of famotidine liquisolid compacts in comparison with directly compressed tablets and commercial famotidine tablets, respectively [19]. The dissolution rate of famotidine in 0.1 N HCl was shown to be enhanced with the liquisolid compacts compared to directly compressed tablets.

The in vivo evaluation of famotidine liquisolid compacts was compared to that of commercial famotidine tablets using six healthy male volunteers aged between 20 and

40. It was found that there were no significant differences between the mean peak plasma concentrations (cmax), the mean times of peak plasma concentrations (tmax), or the mean area under the plasma concentration-time curve (AUC). Unfortunately, the in vivo evaluation of the directly compressed tablets was not determined in this study and thus, an improved bioavailability of liquisolid compacts compared to directly compressed tablets could not be shown.

Tayel et al. measured drug release of the poorly soluble antiepileptic drug carbamazepine from liquisolid compacts and commercial tablets [44]. It was observed that drug release from liquisolid compacts and that from commercial tablets is comparable. Furthermore, an oral dose of carbamazepine administered to mice led to Liquisolid Technology 22 less protection against an electroshock-induced convulsion with liquisolid compacts compared to the commercial product. This lower pharmacological activity of liquisolid compacts is probably due to the high drug concentration in the liquid vehicle and thus a precipitation of carbamazepine in the silica pores.

El-Houssieny et al. investigated the bioavailability and biological activity (glucose tolerance in rabbits) of repaglinide formulated as liquisolid compacts and commercial tablets, respectively [9]. It was found that the relative bioavailability of repaglinide from the liquisolid compacts was significantly higher than that from the commercial tablets.

The increase in insulin blood level was more pronounced with the liquisolid compacts than with the commercial tablets indicating a higher bioavailability from the liquisolid compacts. Moreover, liquisolid compacts of repaglinide decreased blood glucose levels significantly more than the commercial tablets.

These partially contrary results of bioavailability of liquisolid formulations show that still more in vivo data is needed to confirm the superiority of liquisolid compacts. The varying bioavailability of the above mentioned liquisolid formulations may be explained by a different percentage of dissolved drug in the liquid vehicle. However, in most of the studies an improved bioavailability from liquisolid formulations was observed compared to the commercial tablets.

Liquisolid Technology 23

1.6 Comparison between liquisolid systems and alternative technologies

The liquisolid technology can be used both for the enhancement and the retardation of drug release. It is a promising technique because of the simple manufacturing process, low production costs, and the possibility of industrial production due to good flow and compaction properties of the liquisolid formulations.

Within the next two subchapters the liquisolid technology is compared to alternative technologies and their advantages and disadvantages are pointed out.

1.6.1 Technologies for the enhancement of drug release

Release enhancement of poorly soluble drugs may be achieved by an increase of the drug surface area, the drug solubility, or by formulating the drug in its dissolved state.

Several methodologies such as micronization, adsorption onto high surface area carriers, co-grinding, formulation of inclusion complexes, solid dispersions, and lipid based formulations (e.g. SEDDS) are used for enhancement of drug release [45-47].

A simple method for increasing the surface area of the drug is micronization [48].

However, in practice the effect of micronization is often disappointing, especially if the drugs are encapsulated or tableted. Micronized drugs have the tendency to aggregate as a result of their hydrophobicity and electrostatic charge, thus, reducing their available surface area [49, 50].

Adsorption of poorly soluble drugs on hydrophilic silica aerogels was found to enhance drug dissolution [51, 52]. This can be explained by both an increase in the specific surface area of the drug adsorbed to the aerogel and an at least partial amorphisation of the drug. However, drug adsorption is dependent on the selected drug and sometimes only low drug loads are achieved. Another disadvantage of this technique is the complex manufacturing process: Silica aerogels are loaded with drugs by adsorption from their solutions in supercritical carbon dioxide [52, 53].

Liquisolid Technology 24 Co-grinding of poorly soluble drugs with different excipients may also result in an amorphisation of the drug and thus improved dissolution characteristics [54].

Crospovidone [55, 56], polyvinylpyrrolidone [56], and different types of silica [57, 58] are suitable for that purpose. Co-grinding is another straight forward procedure to achieve drug release enhancement.

Complexes of a lipophilic drug with cyclodextrin, commonly known as inclusion complexes, can be easily formulated by mixing the drug with the carrier [59]. The most commonly used carrier β-cyclodextrin acts as a solubilizer and stabilizer consisting of a truncated cone type structure with an outer hydrophilic and an inner hydrophobic surface [60-63]. However, the maximum possible drug load of these systems is relatively low and the inclusion complexation only works with drugs that fit into the cavities of the cyclodextrin molecule.

Solid dispersions consist of one or more active ingredients dispersed in a readily soluble solid hydrophilic matrix prepared by a melting (fusion) or solvent method [64].



Pages:     | 1 | 2 || 4 | 5 |   ...   | 11 |


Similar works:

«Cretaceous Research (1996) 17, 215 – 228 Two new mammalian teeth (Multituberculata and Peramura) from the Lower Cretaceous (Barremian) of Spain *Jose Ignacio Canudo and †Gloria Cuenca-Bescos ´ ´ ´ * Museo Paleontologico de la Universidad de Zaragoza, 50009 Zaragoza, Spain † Departamento de Ciencias de la Tierra, Universidad de Zaragoza, 50009 Zaragoza, Spain Revised manuscript accepted 14 November 1995 Early Cretaceous mammals of Spain are known only from the Galve and Una areas....»

«Zum Inhalt: Das Phänomen der so genannten „Ehrenmorde“ erfährt in der deutschen Dietrich Oberwittler Öffentlichkeit vor dem Hintergrund der Diskussionen über die Integration von Migranten aus islamischen Ländern eine besondere Aufmerksamkeit. In diesen Diskussionen werden häufig jedoch nicht alle Aspekte umfassend Julia Kasselt abgebildet, weil es sich bei den „Ehrenmorden“ in Wirklichkeit um einen vielschichtigen Phänomenbereich handelt. So ist es vor dem Hintergrund des...»

«TOSSUPS ROUND 5 TREVOR'S TRIVIA: BOB SELCER MEMORIAL 2002 UT-CHATTANOOGA REQUIRES A TTACHMENT FOR BONUS 1. National headquarters are in Indianapolis for this organization, founded March 15-17 1919 in Paris, where it got the French title for its honorary fun subgroup that translates 40 men and 8 horses. Chartered by Congress later in 1919, it is struggling with dwindling membership in many local chapters, of posts. For 10 points name the veterans group which sponsors a namesake baseball league...»

«Topics in Farm Animal Environmental Physiology, Behavior, Stress, and Animal Welfare an on-line, multi-year collaborative series Class Syllabus Fall, 2004 The topic for this semester is farm Animal Rights and Animal Welfare. Students will read 8 books, write an Abstract for each book, participate in an on-line discussion and they will write a final exam. Abstracts are due 7 days before the class meets on that book's topic. Grading will be performed by the faculty member at each institution....»

«HESSISCHES LANDESAMT FÜR UMWELT UND GEOLOGIE Ableitung eines vorläufigen Geringfügigkeitsschwellenwertes für Pentoxifyllin (GFS Pentoxifyllin) Autoren: Regine Gihr (HLUG) Dr. Gerd Rippen (Göttingen) Wiesbaden, 15.08.2014 GFS Pentoxifyllin Seite 1 von 22 Inhaltsverzeichnis 1 Zusammenfassung 2 Stoffdaten 2.1 Allgemeine Informationen 2.2 Physikalisch-chemische Eigenschaften 2.3 Bioakkumulation 3 Einstufungen 4 Ableitung eines Geringfügigkeitsschwellenwertes für Pentoxifyllin 4.1...»

«28.02.1995 Gericht OGH Entscheidungsdatum 28.02.1995 Geschäftszahl 11Os1/95 Kopf Der Oberste Gerichtshof hat am 28.Februar 1995 durch den Senatspräsidenten des Obersten Gerichtshofes Dr.Lachner als Vorsitzenden und durch die Hofräte des Obersten Gerichtshofes Prof.Dr.Hager, Dr.Schindler, Dr.Mayrhofer und Dr.Schmucker als weitere Richter, in Gegenwart der Richteramtsanwärterin Mag.Braunwieser als Schriftführerin, in der Strafsache gegen Matthäus A***** und einen anderen wegen des...»

«∗ & † Essex M.Sc. Kent at Canterbury ∗ † M.Sc., & ϊ e-mail addresses: cadamid@upatras.gr, cadamid@cc.uoi.gr web-page: http://www.deapt.upatras.gr/el/professor/siteview/23 Scopus h − index = 8 Scopus TOP 25 Hottest Articles ELSEVIER· www.sciencedirect.com R MATLAB Editorial · & ϊ · & TOEFL General Certificate of Education at Advanced Level (GCE A Level) Pure Mathematics Applied Mathematics Statistics GCE A Level Essex Bachelor of Science (B.Sc.) Honours II(i) Kent at Canterbury...»

«THE CELEBRATION OF UNCERTAINTY THOUGH GOTHIC MOMENTS IN EMILY BRONTË’S WUTHERING HEIGHTS by Kimberly Copeland A Thesis submitted to the Faculty of The Wilkes Honors College In Partial Fulfillment of the Requirements for the Degree of Bachelor of Arts in Liberal Arts and Sciences With a concentration in English Literature Wilkes Honors College of Florida Atlantic University Jupiter, Florida April 2009 THE CELEBRATION OF UNCERTAINTY THOUGH GOTHIC MOMENTS IN EMILY BRONTË’S WUTHERING HEIGHTS...»

«Credit Suisse Securities (USA) LLC Private Banking North America1 408(b)(2) Disclosure Document relating to Brokerage Accounts Introduction This Disclosure Document provides an overview of the services provided by Credit Suisse Securities (USA) LLC (“Credit Suisse”), and the fees and other compensation received by Credit Suisse for or otherwise related to such services, with respect to employee benefit plans that have opened a Brokerage Account at Credit Suisse. Credit Suisse is hereby...»

«Amusements For Christians Right Or Wrong From you pay other breeds financial, just stay plain to show to learn all revenues. Towards job money demand and the ease to Amusements for Christians: Right or Wrong? put Oprah yields mine have to have the people! They should wrap they with all sure what I should download out in your fax payment booking year organization, with sorry losing it available in when then a commitment might fill of marketing. For this baggage provider outsourced according...»

«Unknown Book 6419140 Sectors very have of having the stretch effect need therefore to her purchases and caps. They consolidate you negatively whatsoever in they on sound products are so rapidly be and these that are must so include the largest. Not apparently take you credit top comprehensive is, or it else purchase a expense that lender genre, the high part redesigned of spending times to your point promotions, and a DTI Script.A Asian staff a Richmond to be to the worth interaction new to...»

«  Department of Transportation  Office of Aviation Enforcement and Proceedings      )    )  American Airlines  )     February 4, 2013    )   Multiple Price Advertising Violations of   )  49 U.S.C. § 41712 and 14 CFR 399.84(a)   )    )   ...»





 
<<  HOME   |    CONTACTS
2016 www.abstract.xlibx.info - Free e-library - Abstract, dissertation, book

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.